Stirling fishes for trout

By Dylan Bushell-Embling
Tuesday, 15 July, 2008

Stirling Products North America, a subsidiary of Perth's Stirling Products [ASX: STI] has demonstrated the results of its research into treatment of Loma microsporidial gill disease at an American Fisheries Society meeting.

Loma gill disease, caused by Loma salmonae, is an untreatable disease commonly found in farmed fish, particularly in Pacific salmon and trout.

Research conducted by Stirling demonstrates that the company's ProVale product was more effective at inhibiting Loma infection in rainbow trout when compared with unlicensed products.

ProVale is a beta glucan extract designed to stimulate the immune system.

Content from other channels on our network

Businesses use AI to manage sustainability reporting

Victorian wind farm project to power 1.2 million homes

SA retirement village reduces energy costs using solar system

Battery-free sensors close to reality

How do we prepare for a hotter, more populated, Sydney?

A high-speed, real-time optical data connection for industrial applications

Redesigning for decarbonisation: the shift towards electrified hydraulic power

Chinese humanoid robot manufacturer opens mass production plant

A guide to a cost-effective SIS

NSW launches Local Jobs First Commission legislation

Six key pillars of frailty prevention and management

Protecting the people who protect us: PPE continuity during demand surge

WA steps in to ensure 'continuity' of operations at Mount Private Hospital

What healthcare boards need from risk leaders

Additional $22.9m in research grants for nation's biggest killer

Stirling fishes for trout

AusBiotech partners with Tenmile

Australian CDC issues update in wake of Ebola outbreak

Australia announces $7.2m diphtheria outbreak response package

Content from other channels on our network